Objective To assess the efficacy and safety of golimumab in patients with active psoriatic
arthritis (PsA). Methods Adult patients with PsA who had at least 3 swollen and 3 tender joints …

Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing
spondylitis (AS) in the GO‐RAISE study. Methods Patients with active AS, a Bath AS Disease …

Objective: The phase III GO-FORWARD study examined the efficacy and safety of golimumab
in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. Methods: …

Background Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid
arthritis, but whether use of a different TNFα inhibitor can improve patient response is …

Background: Tumor necrosis factor-α is present in arteries in giant cell arteritis. Objective: To
evaluate the efficacy of infliximab, an anti–tumor necrosis factor-α agent, in giant cell arteritis…

Objective To assess the safety and efficacy of golimumab in methotrexate (MTX)–naive
patients with active rheumatoid arthritis (RA). Methods MTX‐naive patients with RA (n = 637) …

Background Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We
compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits …

Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid
arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐…

Background The interleukin-23 pathway is implicated genetically and biologically in the
pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (…

Objective To assess the efficacy, safety, and pharmacology of subcutaneous administration
of golimumab in patients with active rheumatoid arthritis (RA) despite treatment with …